Viewing Study NCT01649050


Ignite Creation Date: 2025-12-24 @ 4:49 PM
Ignite Modification Date: 2025-12-29 @ 10:41 AM
Study NCT ID: NCT01649050
Status: WITHDRAWN
Last Update Posted: 2017-04-20
First Post: 2012-07-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis
Sponsor: Novartis Pharmaceuticals
Organization:

Study Overview

Official Title: A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Assess the Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis
Status: WITHDRAWN
Status Verified Date: 2014-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To evaluate efficacy and safety of BGG492 versus placebo on moderate to severe spasticity due to multiple sclerosis
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2012-002783-27 EUDRACT_NUMBER None View